Daiwa Securities Group Inc. Has $3.51 Million Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Daiwa Securities Group Inc. raised its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 3.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 31,811 shares of the medical device company’s stock after buying an additional 1,102 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Cooper Companies were worth $3,510,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in Cooper Companies by 3.0% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 7,820,590 shares of the medical device company’s stock worth $682,738,000 after acquiring an additional 231,155 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Cooper Companies by 23.0% in the 3rd quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock valued at $435,856,000 after purchasing an additional 737,726 shares during the period. Impax Asset Management Group plc increased its stake in Cooper Companies by 31.0% during the 2nd quarter. Impax Asset Management Group plc now owns 2,359,798 shares of the medical device company’s stock worth $205,511,000 after purchasing an additional 558,886 shares in the last quarter. Champlain Investment Partners LLC raised its holdings in Cooper Companies by 8.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,818,345 shares of the medical device company’s stock worth $200,636,000 after buying an additional 134,875 shares during the period. Finally, Swedbank AB lifted its stake in Cooper Companies by 16.6% in the second quarter. Swedbank AB now owns 1,600,420 shares of the medical device company’s stock valued at $139,717,000 after buying an additional 228,000 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CAO Agostino Ricupati sold 1,601 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total transaction of $172,956.03. Following the transaction, the chief accounting officer now owns 4,818 shares in the company, valued at approximately $520,488.54. This trade represents a 24.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Daniel G. Mcbride sold 114,992 shares of Cooper Companies stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total value of $12,129,356.16. Following the sale, the chief operating officer now directly owns 44,696 shares of the company’s stock, valued at approximately $4,714,534.08. The trade was a 72.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 256,373 shares of company stock valued at $27,637,427 over the last ninety days. 2.00% of the stock is currently owned by company insiders.

Cooper Companies Price Performance

Shares of COO opened at $103.43 on Thursday. The company’s fifty day simple moving average is $105.59 and its 200 day simple moving average is $98.45. The Cooper Companies, Inc. has a 1-year low of $82.21 and a 1-year high of $112.38. The company has a market cap of $20.60 billion, a price-to-earnings ratio of 57.62, a PEG ratio of 2.21 and a beta of 0.99. The company has a current ratio of 1.99, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.05. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $997.30 million. During the same period last year, the firm posted $0.84 earnings per share. The business’s revenue was up 7.8% on a year-over-year basis. On average, research analysts forecast that The Cooper Companies, Inc. will post 3.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

COO has been the topic of a number of research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a report on Wednesday. Wells Fargo & Company lifted their price target on Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Piper Sandler upped their price objective on Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Stifel Nicolaus reissued a “buy” rating and issued a $115.00 target price (up previously from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. Finally, StockNews.com downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $117.00.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.